Join to access to all OVN content. Join for Free
The most difficult parts of being an MSL and how to overcome them
MSL career KOL relationships MSL challenges time management strategies overcoming MSL burnout

The most difficult parts of being an MSL and how to overcome them


Share This Article


Summary

In this episode, Tom Caravela speaks with Jonathan Horvath about his career journey and insights from the Rutgers fellowship program. Jonathan discusses the complexities and challenges of the MSL role, including organization, territory management, and building relationships with key opinion leaders (KOLs). He addresses internal pressures, performance metrics, and shares strategies for effective time and travel management to combat MSL burnout. The conversation explores navigating different KOL personalities and preparing for meetings. Jonathan also reflects on adapting to COVID-19 and future interactions, offering final advice for aspiring and current MSLs.

My guest today is Jonathan Horvath, former Director of Field Medical Affairs at Dova Pharmaceuticals and we discuss the most difficult parts of being an MSL and how to overcome them.

In this episode we discuss:

  • Jonathan’s background
  • One of the most challenging parts of being an MSL in his perspective
  • KOL access
  • The internal pressures and how to overcome
  • Other challenges and difficulties that MSLs should be aware of to try to stay on top
  • His advice on “MSL frustrations”
  • Advice for MSLs moving into 2021 hopefully coming out of COVID pandemic for them to perform well and get through the challenges
  • One piece of advice for MSLs to help them find success

Click for Source
MSL career, KOL relationships, MSL challenges, time management strategies, overcoming MSL burnout

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Job Search Checklist for Aspiring Medical Science Liaisons
Partner Avatar Tom Caravela

Job Search Checklist for Aspiring Medical Science Liaisons

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Explore OVN